-Advertisement-
-Advertisement-
Genetic and Congenital
Trofinetide shows promise for Rett syndrome in Phase 3 study
In a Phase 3 clinical trial, trofinetide, a synthetic analog of a specific protein, has shown promising results in treating the core symptoms of Rett syndrome, according to a study. The study demonstrated significant improvements in behavior, global impression, and communication abilities in individuals with Rett syndrome who received trofinetide...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
Videos
-Advertisement-
Contact
© 2024 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved